Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service bronchoscopy & lung nodule cases in New Jersey: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 20 | 1,313 | 33% |
| 2020 | 15 | 1,044 | 36% |
| 2021 | 18 | 1,318 | 39% |
| 2022 | 23 | 1,500 | 41% |
| 2023 | 29 | 1,691 | 43% |
| 2024 | 36 | 2,104 | 45% |
| 2025 from claims | – | 2,520 2,313–2,667 | 46% |
| 2026 forecast | – | 2,772 2,438–3,198 | 46% |
| 2027 forecast | – | 3,041 2,600–3,624 | 47% |
| 2028 forecast | – | 3,337 2,784–4,086 | 47% |
| 2029 forecast | – | 3,661 2,990–4,591 | 47% |
| 2030 forecast | – | 4,016 3,218–5,147 | 48% |
EBUS, navigational and robotic bronchoscopy, endobronchial valves, VATS lobectomy. Professional codes (what the surgeon bills): CPT 31652, 31653, 31628, 31647, 32663.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 55% of the cases CMS names in New Jersey; 20 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 24% inpatient hospital, 76% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~2,800 | ~630 | ~2,100 |
| 2027 · ~3,000 | ~670 | ~2,400 |
| 2028 · ~3,300 | ~730 | ~2,600 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 22% (24% in 2025), hospital outpatient about 78% (76% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Pennsylvania | 75 | 5,343+1.2%/yr | +1.2%/yr | 4.0 | 0% | 7,380 in 2030+5.5%/yr |
| New York | 82 | 4,973+1.9%/yr | +1.9%/yr | 2.8 | 0% | 7,320 in 2030+6.6%/yr |
| Massachusetts | 48 | 3,057+5.5%/yr | +5.5%/yr | 3.3 | 0% | 4,980 in 2030+8.5%/yr |
| Connecticut | 12 | 1,083+3.5%/yr | +3.5%/yr | 3.3 | 0% | 2,100 in 2030+12%/yr |
| New Hampshire | 8 | 422+0.3%/yr | +0.3%/yr | 1.9 | 0% | 790 in 2030+11%/yr |
| Maine | 3 | 224−7.6%/yr | −7.6%/yr | 1.4 | 0% | 320 in 2030+6.4%/yr |
| Vermont | 4 | 192+6.8%/yr | +6.8%/yr | 1.7 | 0% | 560 in 2030+20%/yr |
| Rhode Island | 4 | 147+4.9%/yr | +4.9%/yr | 1.6 | 0% | 310 in 2030+13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 581 | 123,352−1%/yr | −1%/yr | 121.51.0× | 59% | 138,300 in 2030+1.9%/yr |
| ERCP & endoscopic ultrasound | 46 | 3,131−1%/yr | −1%/yr | 3.00.8× | 3% | 3,440 in 2030+1.6%/yr |
Bronchoscopy & lung nodule in every state, and its device makers · Every procedure market in New Jersey · Every state · Compare with Pennsylvania
Capsovision leads with 29% of company spending on these surgeons in 2025, +14 pts on 2024.
In 2025, 24 companies reported engagement with New Jersey’s surgeons worth $120K in consulting, speaking, meals and travel tied to these products, about $3,322 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.